News

Vator Securities advises SciBase on 25 MSEK Rights Issue

27 March 2020

Vator Securities acts as Financial Adviser in connection with the transaction raising SEK 25 million.

The capital raised in the rights issue will primarily be used to increase the market presence and penetration of SciBase in the US market where an FDA approval of Nevisense 3.0 is expected during the second quarter of 2020.

Read More

Swiss Nordic Bio 2020

3 February 2020

Swiss Nordic Bio in Zurich is a high-level partnering and investor event where Swiss and Nordic biotech startups, pharmaceutical companies and investors meet.

Swiss Nordic Bio 2020 will be held on 6 February in Zurich and is a collaboration between Vator Securities, the Embassy of Sweden, the Norwegian Embassy, Business Sweden and Business Finland.

Read More

This website uses cookies

Cookies consist of small text files. They contain data that is stored on your device. To enable us to place certain types of cookies we need to obtain your consent. At Vator Securities AB, corp. ID no. 556795-7260, we use the following kinds of cookies. To read more about which cookies we use and storage times, click here to access our cookies policy.

Manage your cookie-settings

Necessary cookies

Necessary cookies are cookies that must be placed for basic functions to work on the website. Basic functions are, for example, cookies which are needed so that you can use menus on the website and navigate on the site.

Functional cookies

Functional cookies need to be placed on the website in order for it to perform as you would expect. For example, so that it recognizes which language you prefer, whether or not you are logged in, to keep the website secure, remember login details or to be able to sort products on the website according to your preferences.

Cookies for statistics

For us to measure your interactions with the website, we place cookies in order to keep statistics. These cookies anonymize personal data.
Confirm choices Accept all